Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 TrialBernard Zinman, Kuninobu Takai, Stewart B. Harris et al.|Diabetes Care|2019Cited by 282
Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective <scp>LIGHT</scp> (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) StudyTakashi Sasaki, Masahiro Fukuda, Masahiro Sugawara|Journal of Diabetes Investigation|2018Cited by 120